Navigation Links
New Incentives to Help Combat Antimicrobial Resistance, but Overuse of Strong Antibiotics Still Needs to Be Curbed
Date:7/12/2012

ROUND ROCK, Texas, July 12, 2012 /PRNewswire/ -- The FDA Safety Innovation Act (FDASIA), signed yesterday, provides pharmaceutical manufacturers with an extended window of antibiotic formulary exclusivity. This incentive should increase drug innovation, but it doesn't address increasing antimicrobial drug resistance, according to noted expert, Dr. David Khan of The University of Texas Southwestern Medical Center in Dallas.

"Too often, a patient's self-reported penicillin allergy causes broad antibiotics to be prescribed even though penicillin was the most appropriate treatment. However, studies show in nine out of ten cases, patients reporting a penicillin allergy are non-allergic," said Dr. Khan.

"Test before treating with non-penicillin antibiotics. With a simple, quick allergy skin test, doctors can easily and inexpensively determine if penicillin is an option," said Dr. Roland Solensky of the Corvallis Clinic.

"Overuse of broad spectrum antibiotic leads to antimicrobial resistance and the need for more powerful antibiotics, which have more toxic side effects," said Dr. Solensky, who wrote the drug allergy practice guidelines.

"By denying a potentially effective treatment, these patients are susceptible to the overuse of broad spectrum antibiotics, leading to increased drug-resistant bacteria," said Jose A. Moreno Toscano, President of ALK-Abello, Inc.

PRE-PEN® (benzylpenicilloyl polylysine injection USP), a skin test product widely used for more than 30 years, can help medical staff quickly identify patients who can safely receive penicillin, opening up a wider range of options and saving lives in the process.

About ALK
ALK holds worldwide rights to market and distribute PRE-PEN® (benzylpenicilloyl polylysine injection USP) penicillin skin testing product. PRE-PEN® (benzylpenicilloyl polylysine injection USP) is currently approved and sold in the USA and Canada.

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy), a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. The company has approximately 1,400 employees with subsidiaries, production facilities and distributors worldwide. ALK was named one of the Best Companies to Work for in Texas in 2012 by www.BestCompaniesTX.com. Further information is available at www.alk-abello.us.

Contact Information:
Lisa Lawrence
For ALK
512-426-4904
Lisa.Lawrence@hcbhealth.com


'/>"/>
SOURCE ALK
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
2. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
3. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. UN emission market needs urgent reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... announced that it has become a Wonderware Certified System Integrator Partner. Huffman ... by Schneider Electric Software. , “The System Integrator Partner certification gives customers confidence ...
(Date:12/7/2016)... Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the ... be presented at the Company,s Annual and Special Meeting. ... will take place on Thursday, December 15, 2016 at ... (Room EC1040), 4825 Mount Royal Gate SW, ... notice of meeting and management information circular, containing the matters ...
(Date:12/7/2016)... India , December 8, 2016 The report "Acrylic Processing ... & Construction, Packaging, Automotive, Consumer Goods) - Global Forecast to 2026", published by ... projected to reach USD 1,173.6 Million by 2026, registering an of CAGR of ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 7, 2016  Muse bio, a privately-held company leading ... that Dr. Kevin Ness has been appointed ... Directors. Kevin succeeds Muse bio,s founding ... Chief Science Officer as well as remains Slade Professor, ... BioDesign Center at the RAS Energy Institute at the ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
Breaking Biology News(10 mins):